Printer Friendly

Micro Therapeutics' Onyx(R) Demonstrated in Live Cases to Clinicians At LINC 2001.

IRVINE, Calif., Oct. 17 /PRNewswire/ --

Micro Therapeutics, Inc. (Nasdaq: MTIX) today said its flagship product, Onyx(R), an innovative treatment for conditions that can lead to stroke, and related products were presented and demonstrated in two successful live cases to leading interventional neuroradiologists from around the world at LINC 2001 in Paris, France.

LINC is a three-day endovascular neuroradiology workshop organized by Professor Jacques Moret, chief of interventional neuroradiology at the Foundation Rothschild in Paris, that provides participants a unique opportunity to view live clinical demonstrations of the latest procedures and state-of-the-art devices for neuro-intervention. A team led by Prof. Moret utilized Onyx in two cases, and debuted the newest generation of several Micro Therapeutics (MTI) products, including micro catheters, guidewires and occlusion balloons.

"LINC provides practitioners of endovascular neuroradiology the most current products, procedures and research," said John Rush, Micro Therapeutic's president and chief executive officer. "MTI is a leading developer of medical devices in this emerging area, and I was pleased Prof. Moret was able to showcase several of MTI's' recent introductions."

The first case performed by Prof. Moret's team involved a large aneurysm in the carotid artery. Despite tortuous anatomy, the team was able to access the aneurysm site with MTI's new X-pedion(TM) Guidewire, and successfully fill the aneurysm with Onyx using MTI's Rebar Micro Catheter and new HyperGlide Balloon. In the second case, a massive arteriovenous malformation (AVM) in the brain was successfully embolized using Onyx with MTI's new UltraFlow Flow Directed Catheter.

About Onyx

Onyx is a liquid embolic material that is delivered through MTI's proprietary micro catheters directly into a targeted vascular malformation, such as a brain aneurysm or AVM. Once inside the targeted malformation, the liquid quickly transforms into a spongy polymer mass designed to seal off the malformation from blood flow. Onyx is non-adhesive, which enhances controllability during delivery, and it is visible under fluoroscopy -- allowing clinicians a clear view of the embolization procedure in real-time.

In Europe, MTI has received CE Mark to commercially promote Onyx for use in the treatment of aneurysms, AVMs and certain peripheral applications. In the U.S., the company is conducting pivotal clinical trials that are studying the use of Onyx in the treatment of aneurysms and AVMs. Worldwide, across all therapies, Onyx has been used in more than 1,300 procedures.

Statements contained in this press release which are not historical information, are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected or implied. Such potential risks and uncertainties include, but are not limited to, in no particular order: the company's ability to build a sales force in Europe, the impact of terminating its distribution agreement with Guidant Corporation, product development, risks and results of clinical testing, demand and market acceptance risks, the impact of competitive products and pricing, regulatory approval and future product development. More detailed information on these and additional factors which could affect Micro Therapeutics, Inc.'s operating and financial results are described in the company's prospectus dated February 18, 1997, as well as in its Forms 10-QSB, 10-KSB and other reports, filed or to be filed with the Securities and Exchange Commission. Micro Therapeutics, Inc. urges all interested parties to read these reports to gain a better understanding of the many business and other risks that the company faces. Additionally, Micro Therapeutics, Inc. undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.

COPYRIGHT 2001 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 17, 2001
Previous Article:R&G Financial Reports Record Earnings for Third Quarter And Nine Months Ended September 30, 2001.
Next Article:Bell Microproducts Releases Third Quarter Results.

Related Articles
MTI's Onyx LES(TM) Receives Positive Review at LINC Conference.
Micro Therapeutics Reports on Onyx LES AVM Program Developments; Expansion in Europe Augmented by Conditional FDA Approval of Study in U.S.
Micro Therapeutics Obtains FDA Approval to Begin Pivotal Trial of Onyx For Aneurysms.
Micro Therapeutics Receives FDA Approval for Pivotal Trial of Onyx For Arteriovenous Malformations.
Micro Therapeutics Reports Record Sales in 2001 First Quarter.
Micro Therapeutics Reports Record Sales in 2001 Second Quarter.
Micro Therapeutics Announces Plan to Establish European Sales Force For Onyx(TM).
Micro Therapeutics Reports 2001 Third Quarter Financial Results.
Micro Therapeutics Presents Favorable Interim Results in European Aneurysm Registry; - Company Updates Progress on U.S. Clinical Trial Enrollment -...
Micro Therapeutics Reports 2001 Fourth Quarter and Full Year Financial Results; - Conference Call Scheduled Today at 11:00 a.m. PST; Simultaneous...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters